Optical molecular imaging in oral- and oropharyngeal squamous cell carcinoma using a novel uPAR-targeting near-infrared imaging agent FG001 (ICG-Glu-Glu-AE105): An explorative phase II clinical trial. [PDF]
TheranosticsBackground: In oral and oropharyngeal squamous cell carcinoma (OSCC, OPSCC), frequent inadequate surgical margins highlight the importance of precise intraoperative identification and delineation of cancerous tissue for improving patient outcomes ...
Andersen AO +12 more
europepmc +6 more sources
Gallium Ga 68-NOTA-AE105 [PDF]
Definitions, 2020 A radiotracer composed of AE105, an urokinase-type plasminogen activator receptor (uPAR) peptide antagonist, conjugated with the bifunctional, macrocyclic chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOT A) and labeled with the ...
semanticscholar +2 more sources
Definitions, 2020 A radiotracer composed of AE105, a urokinase-type plasminogen activator receptor (uPAR) peptide antagonist, conjugated with DOT A and labeled with the radionuclide copper Cu 64, with potential imaging activity upon positron emission tomography (PET ...
semanticscholar +2 more sources
Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer. [PDF]
Cancers (Basel), 2022 Several studies have ascertained that uPA and uPAR do participate in tumor progression and metastasis and are involved in cell adhesion, migration, invasion and survival, as well as angiogenesis.
Masucci MT +4 more
europepmc +3 more sources
Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with <sup>18</sup>F-FDG PET/CT: A Single-Center Prospective Study. [PDF]
J Nucl Med, 2022 Visual Abstract The aim of this phase II clinical trial (NCT02965001) was to evaluate the prognostic value of urokinase-type plasminogen activator receptor (uPAR) PET/CT with the novel ligand 68Ga-NOTA-AE105 in head and neck cancer and compare it with ...
Risør LM +8 more
europepmc +2 more sources
Design and Preclinical Evaluation of Novel uPAR-Targeting Radiopeptides Modified with an Albumin-Binding Entity. [PDF]
Mol PharmSeveral studies have focused on the development and application of radiolabeled DOTA-AE105 for targeting the urokinase-type plasminogen activator receptor (uPAR), which is expressed on various cancer types.
Beyer D +6 more
europepmc +2 more sources
uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer:Proof-of-concept in orthotopic xenograft model [PDF]
OncoTarget, 2016 PURPOSE: Urokinase-like Plasminogen Activator Receptor (uPAR) is overexpressed in a variety of carcinoma types, and therefore represents an attractive imaging target. The aim of this study was to assess the feasibility of two uPAR-targeted probes for PET
Charabi, Birgitte Wittenborg +9 more
core +2 more sources
Oncology Letters, 2015 The elevated expression of urokinase-type plasminogen activator receptor (uPAR) is associated with the poor prognosis of pancreatic cancer patients. Thus, uPAR is a promising candidate as a molecular target for the non-invasive imaging of pancreatic ...
Xin Zhang +6 more
semanticscholar +4 more sources
Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial. [PDF]
J Nucl Med, 2021 The aim of this study was to evaluate the correlation between uptake of the PET ligand 68Ga-NOTA-AE105, targeting the urokinase-type plasminogen activator receptor (uPAR), and Gleason score in patients undergoing prostate biopsy.
Fosbøl MØ +10 more
europepmc +2 more sources